Contact:

The Quigley Corporation Convenes Scientific Advisory Board for Quigley Pharma

DOYLESTOWN, PA, December 12, 2002 - The Quigley Corporation (NASDAQ: QGLY), today announced that Quigley Pharma, Inc. convened the first annual meeting of its new Scientific Advisory Board of leading specialists in medical science and research. Members of Quigley Pharma’s advisory board will review and provide independent advice on research and development activities.

At its first meeting last month, the board reviewed data from current Quigley Pharma studies and discussed the research and regulatory approval processes for several of the compounds currently under development.

“Quigley Pharma is focused on medical discovery in therapeutic areas that have not been successfully covered by major pharmaceutical companies,” said Richard Rosenbloom, MD, Ph.D., chief operating officer of Quigley Pharma. “The Scientific Advisory Board was created as a forum for the company to consult with scientific and clinical opinion leaders who provide valuable feedback for the drug development process.”

Quigley Pharma Scientific Advisory Board members include:

Nicholas Diamond, D.O. of the Diamond Pain Clinic, Elkins Park, Pennsylvania. Dr. Diamond is a researcher in pain and rehabilitation and an editorial board member of the American Journal of Pain Management.

Robert Dworkin, Ph.D., Professor of Anesthesiology, Oncology & Psychiatry, Director of Analgesic Research, University of Rochester Medical Center, Rochester, New York. Dr. Dwokin is chair, International Conference on the Mechanisms and Treatment of Neuropathic Pain. He has served as associate editor of the Clinical Journal of Pain, and on the editorial boards of Pain Medicine and Current Pain and Headache Report.

Mario Guralnik, Ph.D. of Synergy Research, Inc. Synergy Research is a professional independent clinical contract research organization specializing in clinical drug development. Dr. Guralnik is the former medical affairs director of Asta Medica and the author of “Assuring Data Quality and Validity in Clinical Trials for Regulatory Decision Making: Workshop Report.”

Edwin Keates, M.D., of Northern Ophthalmic Associates, Inc., Jenkintown, Pennsylvania. Findings on acute myopia and secondary angle closure glaucoma presented by Dr. Keates at the Annual Meeting of the American Academy of Neurology were recently published in the Johns Hopkins Medical School journal “Advanced Studies in Medicine.”

Peter Lodewick, M.D. of Lodewick Diabetes Center, Birmingham, Alabama. Dr. Lodewick, a diabetic himself, is the author of several books on diabetes.

Philip Raskin, M.D., Professor of Medicine, Department of Internal Medicine, University of Texas, Southwestern Medical Center at Dallas, Texas. He serves as the editor of the Journal of Diabetes Complications and Director of the University Diabetes Treatment Center / Parkland Memorial Hospital, Dallas, Texas.

Mark Lebwohl, MD, Professor & Chairman, Department of Dermatology, Mt. Sinai School of Medicine, New York was unable to attend. Dr. Lebwohl is assistant editor of the Journal of the American Academy of Dermatology. He has chaired numerous symposia and has written or edited several books including Difficult Diagnoses in Dermatology, Psoriasis, and Atlas of the Skin and Systemic Disease. Dr. Lebwohl has authored or co-authored over 400 publications including articles, chapters and abstracts.

Formulas currently undergoing or about to begin clinical trials were given extensive review:

QR333
Quigley Pharma Inc. commenced a proof of concept study on a topical treatment for diabetic peripheral neuropathy. The study is being conducted in France, an E.U. member country. After approval from the French Advisory Committee on the Protection of Research Subjects, The French Ministry of Health approved a Phase II Proof of Concept Study for the Treatment of Diabetic Neuropathy with Topical QR-333 on April 3, 2002. This multi-center, double blind, Placebo-controlled study is being conducted at three hospital sites in Bondy, Never and Le Gau-du-Roi, France.

QR334
QR-334 is a new formulation being developed and tested by Quigley Pharma Inc. to relieve Sialorrhea (excess secretions of the salivary glands, causing drooling) in patients suffering from diseases including Amyotrophic Lateral Sclerosis (ALS), otherwise known as Lou Gehrig's Disease, Cerebral Palsy, Parkinson's Disease, and Muscular Dystrophy among others. The Principal Investigator for this trial is Dr. Stanley H. Appel, Professor and Chairman of the Department of Neurology at the Baylor College of Medicine, Texas Medical Center, in Houston.

The Phase II trial will be a multi center U.S. study that will include approximately 100 patients at clinical sites at Baylor College of Medicine, Houston, Texas, the University of Medicine and Dentistry of New Jersey - Robert Wood Johnson Medical School (UMDNJ-RWJ) and other private clinical research centers in Philadelphia, Louisville, Tampa and LaJolla, California.

About The Quigley Corporation
The Quigley Corporation (NASDAQ: QGLY) is a leading developer and marketer of diversified health products including the Cold-Eeze® family of patented zinc gluconate glycine (ZIGG™) lozenges, gums and sugar free tablets. Cold-Eeze is the only (ZIGG™) lozenge proven in two double-blind studies to reduce the duration of the common cold from 7.6 to 4.4 days or by 42%. In addition to Over-The-Counter (OTC) products, the Company has formed Quigley Pharma Inc. (www.QuigleyPharma.com), a wholly owned ethical pharmaceutical subsidiary, to introduce a line of patented prescription drugs. The Quigley Corporation's customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies.

No claims are being made for the potential medicine discussed in this press release to be safe, effective, or approved by the Federal Food and Drug Administration (FDA).

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, un­certainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.